Lakefront Biotherapeutics (LKFT) Receivables (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Receivables for 13 consecutive years, with $24.7 million the latest figure, recorded in Q1 2026.

• Quarterly Receivables fell 57.5% year-over-year to $24.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $24.7 million (down 57.5% YoY) and the FY2025 annual result came in at $28.2 million, down 57.0% from the prior year.
• Receivables fell to $24.7 million in Q1 2026 per LKFT's latest filing, from $27.9 million in the prior quarter.
• Over the last five years, Receivables for LKFT reached as high as $70.2 million in Q1 2022 and fell as low as $10.5 million in Q4 2024.
• A 5-year average of $47.2 million and a median of $51.7 million in 2024 frame the typical range for Receivables.
• Annual changes were most pronounced in 2024 — Receivables plunged 72.46% — and 2025, when it surged 164.77%.
• Year by year, Receivables stood at $55.0 million in 2022, then tumbled by 30.35% to $38.3 million in 2023, then tumbled by 72.46% to $10.5 million in 2024, then jumped by 164.77% to $27.9 million in 2025, then slipped by 11.41% to $24.7 million in 2026.
• According to Business Quant data, Receivables over the past three periods registered $24.7 million, $27.9 million, and $51.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.